Opinion
Video
POETYK PSO-1 and POETYK PSO-2 Trials for Plaque Psoriasis
Author(s):
Dr April W. Armstrong reviews key findings from the phase 3 POETYK PSO-1 and POETYK PSO-2 clinical trials evaluating the use of deucravacitinib for the treatment of plaque psoriasis.
This is a video synopsis of a discussion involving April W. Armstrong, MD, MPH, Professor and Chief of Dermatology at UCLA, and Chair Emeritus of the Medical Board of the National Psoriasis Foundation. Dr. Armstrong specializes in psoriasis and atopic dermatitis.
Dr. Armstrong highlights the evaluation of deucravacitinib in global populations through two rigorous clinical trials, POETYK PSO-1 and POETYK PSO-2. The trials were randomized, double-blind, and placebo-controlled. Results at week 16 showed a significantly higher response rate with deucravacitinib compared to placebo and the oral medication apremilast.
At week 16, nearly 60% of patients achieved a PASI (Psoriasis Area and Severity Index) 75 response with deucravacitinib, compared to about 35% on Apremilast and 12% on placebo. Similarly, for the outcome of clear or almost clear skin (sPGA01), around 54% of patients achieved this with deucravacitinib compared to 32% on apremilast.
This marks the first large-scale, head-to-head comparison with an active comparator arm, providing definitive insights into the comparative efficacy of deucravacitinib versus apremilast. Additionally, three-year data demonstrates a good maintenance of response with deucravacitinib, with about 75% of patients maintaining PASI 75 at the end of three years.
These findings are crucial for understanding the long-term efficacy and maintenance of response in patients with psoriasis, a chronic condition. It underscores the potential of deucravacitinib as a treatment option for patients with moderate to severe psoriasis, offering sustained benefits over time.
Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.
